EP0641202A1 - Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease - Google Patents
Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's diseaseInfo
- Publication number
- EP0641202A1 EP0641202A1 EP93912699A EP93912699A EP0641202A1 EP 0641202 A1 EP0641202 A1 EP 0641202A1 EP 93912699 A EP93912699 A EP 93912699A EP 93912699 A EP93912699 A EP 93912699A EP 0641202 A1 EP0641202 A1 EP 0641202A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- memory disorders
- parkinson
- disease
- sexual dysfunction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to the use of selective dopamine D3 receptor agonists in therapy, for example in the treatment of memory disorders.
- the present invention resides in the identification of such a utility and, in a first aspect, provides selective dopamine D3 receptor agonists for use in therapy.
- the present invention relates to selective dopamine D3 receptor agonists for use in the treatment or prophylaxis of diseases in which agonism of the D3 receptors will prove advantageous, for example, in the treatment of memory disorders, sexual dysfunction and Parkinson's disease.
- Particular selective dopamine D3 receptor agonists include, for example, compounds of the structure (I) :
- each group R is the same or different and is hydrogen or
- R 1 and R ⁇ are the same or different and are each hydrogen or C ⁇ _4alkyl; and n is 1 to 3, or a pharmaceutically acceptable salt thereof.
- the compound ropinirole and other compounds of structure (I) are known in the art, for example as having utility in the treatment of Parkinson's disease (EP 0299602-A) .
- the compounds of structure (I) and, in particular, ropinirole can be prepared according to the procedures described in EP 113964-B.
- Selective dopamine D3 receptor agonists are of use in therapy, in particular in the treatment of memory disorders, for example, in the treatment of impaired cerebral functionality, as well as dementia, amnesia and decreased cognitive capacity; in the treatment of sexual dysfunction in both males and females, in particular in the treatment of male and female impotence; and in the treatment of Parkinson's disease.
- the compounds of structure (I) are formulated into a standard pharmaceutical composition, for example as described in EP 113964-B and EP 0299602-A.
- each dosage unit for oral administration contains preferably from 1 to 50 mg (and for parenteral administration contains preferably from 0.1 to 15 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
- the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 100 mg, preferably between 1 mg and 50 mg, or an intravenous, subcutaneous, or
- -y intramuscular dose of between 0.1 mg and 50 mg, preferably 5 between 0.1 mg and 15 mg, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
- the compounds will be administered for a period of continuous therapy.
- the membrane pellet was resuspended in ice-cold 50 mM Tris salts (pH 7.4 @ 37°C) , using an Ultra-Turrax, and recentrifuged at 18,000 - A - r.p.m for 15 in at 4°C in a Sorvall RC5C.
- the membranes were washed two more times with ice-cold 50 mM Tris salts (pH 7.4 ⁇ a 37°C) .
- the final pellet was resuspended in 50 mM Tris salts (pH 7.4 @ 37°C) , and the protein content determined using bovine serum albumin as a standard (Bradford, M. M. (1976) Anal. Biochem. 72, 248-254) .
- the binding data revealed the existence of two binding sites in both human D 2 and D3 receptors.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Selective dopamine D3 receptor agonists and their use in therapy, inter alia, in the treatment of memory disorders.
Description
USE OF INDOLONE DERIVATIVES FOR THE TREATMENT OF MEMORY DISORDERS. SEXUAL DYSFUNCTION AND PARKINSON'S DISEASE
The present invention relates to the use of selective dopamine D3 receptor agonists in therapy, for example in the treatment of memory disorders.
Compounds capable of binding selectively to dopamine D3 receptors are known in the art (see, for example, Nature, 1990, 347, 146) . To <iate, however, no specific therapeutic utility has been identified for compounds having such properties.
The present invention resides in the identification of such a utility and, in a first aspect, provides selective dopamine D3 receptor agonists for use in therapy.
More specifically, the present invention relates to selective dopamine D3 receptor agonists for use in the treatment or prophylaxis of diseases in which agonism of the D3 receptors will prove advantageous, for example, in the treatment of memory disorders, sexual dysfunction and Parkinson's disease.
Particular selective dopamine D3 receptor agonists include, for example, compounds of the structure (I) :
(I)
in which, each group R is the same or different and is hydrogen or
C-L_ alkyl;
R1 and R^ are the same or different and are each hydrogen or Cι_4alkyl; and n is 1 to 3, or a pharmaceutically acceptable salt thereof.
Within the scope of the structure (I) and the most preferred selective dopamine D3 receptor agonist of the present invention is the compound 4-(2-di-n-propylaminoethyi)-2- (3H)-indolone hydrochloride having the INN: ropinirole. The compound ropinirole and other compounds of structure (I) are known in the art, for example as having utility in the treatment of Parkinson's disease (EP 0299602-A) .
The compounds of structure (I) and, in particular, ropinirole, can be prepared according to the procedures described in EP 113964-B.
Selective dopamine D3 receptor agonists are of use in therapy, in particular in the treatment of memory disorders, for example, in the treatment of impaired cerebral functionality, as well as dementia, amnesia and decreased cognitive capacity; in the treatment of sexual dysfunction in both males and females, in particular in the treatment of male and female impotence; and in the treatment of Parkinson's disease.
When used in therapy, the compounds of structure (I) , in particular ropinirole, are formulated into a standard pharmaceutical composition, for example as described in EP 113964-B and EP 0299602-A.
Preferably the composition is administered in unit dose form. Each dosage unit for oral administration contains preferably from 1 to 50 mg (and for parenteral administration contains preferably from 0.1 to 15 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
The daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 100 mg, preferably between 1 mg and 50 mg, or an intravenous, subcutaneous, or
-y intramuscular dose of between 0.1 mg and 50 mg, preferably 5 between 0.1 mg and 15 mg, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy.
10
DATA
The ability of the compounds to bind selectively to human D3 dopamine receptors can be demonstrated by measuring their
15 binding to cloned receptors. The inhibition constants (K^) for ropinirole displacement of [125I] iodosulpride binding to human D2 and D3 dopamine receptors expressed in CHO cells have been determined. Human D2 receptors were obtained from Garvan Institute of Medical Research, St. Vincent's
20 Hospital, Darlinghurst, New South Wales 2010, Australia.
Human D3 receptors originated from Unite de Neurobiologie et Pharmacologie (U.109) de 1*INSERM, Centre Paul Broca, 2ter rue d'Alesia, 75014 Paris France (B. Giros (1991) Path. Biol. 39, 252-254) . Crude cell membranes were prepared by
25 homogenisation followed by high-speed centrifugation, and characterisation of cloned receptors achieved by radioligand binding.
Preparation of CHO cell membranes
30
Cell pellets were gently thawed at room temperature, and resuspended in about 20 volumes of ice-cold 50 mM Tris salts (pH 7.4 @ 37°C), 20mM EDTA, 0.2 M sucrose. The suspension was homogenised using an Ultra-Turrax at full speed for 15 35 sec. The ho ogenate was centrifuged at 18,000 r.p.m for 20 min at 4°C in a Sorvall RC5C centrifuge. The membrane pellet was resuspended in ice-cold 50 mM Tris salts (pH 7.4 @ 37°C) , using an Ultra-Turrax, and recentrifuged at 18,000
- A - r.p.m for 15 in at 4°C in a Sorvall RC5C. The membranes were washed two more times with ice-cold 50 mM Tris salts (pH 7.4 ^a 37°C) . The final pellet was resuspended in 50 mM Tris salts (pH 7.4 @ 37°C) , and the protein content determined using bovine serum albumin as a standard (Bradford, M. M. (1976) Anal. Biochem. 72, 248-254) .
Binding experiments on cloned dopamine receptors
Crude cell membranes were incubated with 0.1 n [~^I] iodosulpride (~2000 Ci/mmol; Amersham, U. K.), 50 mM Tris salts (pH 7.4 @ 37°C), 120 mM NaCl, 5 mM KC1, 2 mM CaCl2, 1 mM MgCl2, 0.1% (w/v) bovine serum albumin, in a total volume of 1 ml for 30 min at 37°C. Following incubation, samples were filtered using a Brandel Cell Harvester, and washed three times with ice-cold 50 mM Tris salts (pH 7.4 Q 37°C) , 120 mM NaCl, 5 mM KC1, 2 mM CaCl2 1 mM MgCl2- The radioactivity on the filters was measured using a Cobra gamma counter (Canberra Packard) . Non-specific binding was defined as the radioligand binding remaining after incubation in the presence of 100 μM iodosulpride. For competition curves, 14 concentrations (half-log dilutions) of competing cold drug were used.
Competition curves were analysed simultaneously whenever possible using non-linear least-squares fitting procedures, capable of fitting one, two or three site models.
RESULTS
The binding data revealed the existence of two binding sites in both human D2 and D3 receptors. The inhibition constant {Kj for ropinirole at the high affinity site was found to be 1380 nM (n=5) at D2 and 69.1 nM (n=6) at D3 receptors. These results indicate that ropinirole binds selectively (20 fold) to human D3 dopamine receptors.
Claims
1. A selective dopamine D3 receptor agonist for use in therapy.
2. A selective dopamine D3 receptor agonist for use in the manufacture of a medicament for use in the treatment of memory disorders.
3. A selective dopamine D3 receptor agonist for use in the manufacture of a medicament for use in the treatment of sexual dysfunction.
4. The use according to claim 2 or claim 3 in which the selective dopamine D3 receptor agonist is a compound of the structure (I) :
(I)
in which, each group R is the same or different and is hydrogen or Cι_4alkyl; R1 and R2 are the same or different and are each hydrogen or Cι_ alkyl; and n is 1 to 3, or a pharmaceutically acceptable salt thereof.
5. The compound 4-(2-di-n-propylaminoethyl)-2- (3H)- indolone hydrochloride (INN: ropinirole) for use in the manufacture of a medicament for use in the treatment of memory disorders.
6. The compound 4-(2-di-n-propylaminoethyl)-2-(3H)- indolone hydrochloride (INN: ropinirole) for use in the manufacture of a medicament for use in the treatment of sexual dysfunction.
7. The use of a selective dopamine -D3 receptor agonist other than a compound of structure (I) or a pharmaceutically acceptable salt thereof as described in claim 4, in the manufacture of a medicament for use in the treatment of Parkinson's disease.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9210594 | 1992-05-18 | ||
GB929210595A GB9210595D0 (en) | 1992-05-18 | 1992-05-18 | Medical use |
GB929210576A GB9210576D0 (en) | 1992-05-18 | 1992-05-18 | Medical use |
GB9210595 | 1992-05-18 | ||
GB929210594A GB9210594D0 (en) | 1992-05-18 | 1992-05-18 | Medical use |
GB9210576 | 1992-05-18 | ||
PCT/EP1993/001099 WO1993023035A2 (en) | 1992-05-18 | 1993-05-04 | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0641202A1 true EP0641202A1 (en) | 1995-03-08 |
Family
ID=27266192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93912699A Withdrawn EP0641202A1 (en) | 1992-05-18 | 1993-05-04 | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0641202A1 (en) |
JP (1) | JPH07506823A (en) |
AU (1) | AU4312593A (en) |
WO (1) | WO1993023035A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395744B1 (en) | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
FR2742149B1 (en) * | 1995-12-11 | 1998-02-13 | Inst Nat Sante Rech Med | NOVEL 2-NAPHTAMIDE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
PT923551E (en) * | 1996-08-27 | 2002-09-30 | American Home Prod | 4-AMINOETHOXY INDOLONE DERIVATIVES |
US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
AR014847A1 (en) * | 1998-04-13 | 2001-03-28 | American Home Prod | 4-AMINO- (ETILAMINO) -OOPINDIN OXINDOLS OF THE DOPAMINE SELF-RECEPTOR AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS |
WO1999066909A2 (en) * | 1998-06-22 | 1999-12-29 | Univ Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
CA2251255A1 (en) * | 1998-10-20 | 2000-04-20 | Mcgill University | The use of dopaminergic agents in the management of sexual dysfunction |
AR030557A1 (en) | 2000-04-14 | 2003-08-27 | Jagotec Ag | A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD |
DE10041479A1 (en) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | New pharmaceutical composition for the administration of N-0923 |
DE10359528A1 (en) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic |
MXPA06013759A (en) * | 2004-05-26 | 2007-02-08 | Pfizer | New indazole and indolone derivatives and their use as pharmaceuticals. |
EP2603215A4 (en) | 2010-08-11 | 2015-08-05 | Philadelphia Health & Educatio | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease |
CN105848655B (en) | 2013-10-28 | 2019-11-08 | 德雷克塞尔大学 | For attention and cognitive disorder and for dementia associated with neurodegeneration obstacle new treatment |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452808A (en) * | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
GB8712073D0 (en) * | 1987-05-21 | 1987-06-24 | Smith Kline French Lab | Medicament |
FR2663638B2 (en) * | 1990-04-06 | 1995-02-10 | Institut Nal Sante Recherc Medic | POLYPEPTIDES HAVING DOPAMINERGIC RECEPTOR ACTIVITY, NUCLEIC ACIDS ENCODING SUCH POLYPEPTIDES AND USE OF SUCH POLYPEPTIDES FOR SCREENING ACTIVE SUBSTANCES ON THESE POLYPEPTIDES. |
GB9015095D0 (en) * | 1990-07-09 | 1990-08-29 | Smith Kline French Lab | Therapeutic method |
-
1993
- 1993-05-04 AU AU43125/93A patent/AU4312593A/en not_active Abandoned
- 1993-05-04 JP JP5519830A patent/JPH07506823A/en active Pending
- 1993-05-04 WO PCT/EP1993/001099 patent/WO1993023035A2/en not_active Application Discontinuation
- 1993-05-04 EP EP93912699A patent/EP0641202A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9323035A2 * |
Also Published As
Publication number | Publication date |
---|---|
JPH07506823A (en) | 1995-07-27 |
AU4312593A (en) | 1993-12-13 |
WO1993023035A3 (en) | 1994-03-03 |
WO1993023035A2 (en) | 1993-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9486455B2 (en) | Compounds for modulating TRPV3 function | |
WO1993023035A2 (en) | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease | |
TWI401254B (en) | Compounds for modulating trpv3 function | |
US9181219B2 (en) | Compounds of modulating TRPV3 function | |
JP4264850B2 (en) | Use of epinastine for the treatment of pain | |
TWI404538B (en) | Use of arsenic compounds for treatment of pain and inflammation | |
US8916550B2 (en) | Compounds for modulating TRPV3 function | |
TW498076B (en) | Modified amino acids and pharmaceutical compositions containing these compounds | |
WO1999064011A1 (en) | Drugs | |
JPH06502168A (en) | angiotensin 2 antagonist | |
CN108042542A (en) | For treating the method and composition of illness | |
CA1263654A (en) | Zwitterionic bicyclic compounds and their salts, solvates, hydrates and esters | |
EP0185420A1 (en) | Dihydrocodeine/ibuprofen pharmaceutical compositions and method | |
EP1206264A2 (en) | Compositions and methods for treating opiate intolerance | |
JPS6391391A (en) | 2- or 3-aryl substituted imidazo (1, 2-a) pyridine | |
US20220096482A1 (en) | Combination therapies | |
JP3808921B2 (en) | Cell adhesion inhibitor | |
Walia et al. | Montelukast in pediatric asthma management | |
WO2024016996A1 (en) | Use of naphthoquine phosphate in preparation of medicament for treating autoimmune diseases | |
WO1991007178A1 (en) | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders | |
US20100280061A1 (en) | Novel analgesic that binds filamin a | |
SK8572003A3 (en) | Histamine receptor antagonists | |
IE63194B1 (en) | Antiemesis ergoline derivatives | |
JP3180381B2 (en) | Anti-aldosterone agent | |
JPH1160483A (en) | Tnf production inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19941122 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 19960119 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19960530 |